ZYMFENTRA™ (infliximab-dyyb) demonstrated long-term efficacy and safety profile of maintenance treatment through two years for adults with moderately to severely active Crohn s disease and ulcerative colitis | Taiwan News taiwannews.com.tw - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from taiwannews.com.tw Daily Mail and Mail on Sunday newspapers.
Celltrion today presented positive twoyear results from the extended LIBERTY studies LIBERTYCD1 and LIBERTYUC2 in patients with moderately to severely active Crohns disease CD and ulcerative colitis UC. Celltrion also presented endoscopic outcomes from the posthoc analysis of the LIBERTYCD study.3
Celltrion presents new two-year data for subcutaneous infliximab (CT-P13 SC) in inflammatory bowel disease (IBD) at the 19th ECCO Congress streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.